Islet Sciences, Inc., based in Raleigh, NC, is focused on improving patient outcomes by developing new medicines and technologies for the treatment and diagnosis of metabolic disease. The Company’s pipeline includes small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. Each of the Company’s programs is supported by a robust estate of issued patents and patent applications.

According to the World Health Organization, 347 million people worldwide suffer from diabetes and the disease is projected to be the 7th leading cause of death by 2030. In the United States, there are an estimated 25.8 million diabetics and another 79 million people with pre-diabetes. According to the American Diabetes Association, the direct medical costs associated with diagnosed diabetes in the United States in 2012 were $176 billion.

Islet Sciences, Inc. is developing new medicines and technologies for the diagnosis and treatment of metabolic disease. The Company is developing an encapsulated islet cell transplantation therapy for the treatment of type 1 or insulin-dependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors that protect insulin-producing beta-cells from cytokines responsible for cell destruction; and a PCR based molecular diagnostic measuring hypomethylated beta cell-derived DNA as a biomarker of beta cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes.

latest news

08.06.2014
Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors  
VIEW PDF 

07.29.2014
Letter to Islet Sciences, Inc. (ISLT) Shareholders from CEO James Green  
VIEW PDF 

07.16.2014
Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic  
VIEW PDF 

06.23.2014
Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)  
VIEW PDF 

06.16.2014
Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting  
VIEW PDF 

06.12.2014
Islet Sciences to Present SGLT2 Remogliflozin Phase 2b and Biphasic Formulation clinical data at American Diabetes Association (ADA)  
VIEW PDF 

05.29.2014
Islet Sciences Appoints Steven Delmar Chief Financial Officer 
VIEW PDF 

04.16.2014
Islet Sciences Anounces Positive Phase 2b Clinical Results for SGLT2 Inhibitor Remogliflozin 
VIEW PDF 

03.17.2014
Islet Sciences Anounces a Conference Call to Discuss Acquisition of BHV Pharma
VIEW PDF
 

03.14.2014
Islet Sciences Anounces Dr. Michael Luther Appointed to Islet Sciences Board of Directors
View PDF
 

03.13.2014
Islet Sciences to Acquire BHV Pharma SGLT2 Inhibitor Remogliflozin
View PDF
 

01.06.2014
Dr. Eric Barnett Appointed to Islet Sciences Board of Directors
View PDF
 

12.12.2013
Letter to shareholders from CEO James Green
View PDF
 

10.30.2013
Islet Sciences Appoints James Green as CEO and Dr. Bill Wilkison as COO

 

06.24.13
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
READ MORE

05.10.13
Islet Sciences Article in Insulin Nation Titled “A Type 1 Triple Play”
READ MORE

05.07.13
Islet Sciences Highlights Abstract at Arteriosclerosis, Thrombosis & Vascular Biology ATVB 2013
READ MORE

04.29.13
Islet Sciences Reviews Japanese Patent Covering New Medication for Diabetes.
READ MORE

 

04.03.13
Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders
READ MORE

03.13.13
Islet Sciences Announces Important Study Published in Diabetes Titled “Immune Intervention Reducing β-Cell Death in Type 1 Diabetes”

READ MORE

01.08.13
Islet Sciences Announces Inclusion in BioWorld Today Article .
read more

Islet Sciences Announces Inclusion in BioWorld Today Article --- NEW YORK. NY, January 8, 2013 --Islet Sciences, Inc., (ISLT) a clinical stage...Learn More

Islet Sciences 8601 Six Forks Road Suite 400 Raleigh, NC 27615 Phone: 919.480.1518
Islet Sciences © 2011-2014 · Privacy Policy